nucleospin mirna plasma columns (MACHEREY NAGEL)
MACHEREY NAGEL is a verified supplier 
93
Structured Review
MACHEREY NAGEL
nucleospin mirna plasma columns
Nucleospin Mirna Plasma Columns, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 93/100, based on 96 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/buffer/pmc05131283-126-8-12?v=MACHEREY+NAGEL
Average 93 stars, based on 96 article reviews
Nucleospin Mirna Plasma Columns, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 93/100, based on 96 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/buffer/pmc05131283-126-8-12?v=MACHEREY+NAGEL
Average 93 stars, based on 96 article reviews
nucleospin mirna plasma columns - by Bioz Stars,
2026-08
93/100 stars
Images
1) Product Images from "Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1"
Article Title: Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
Journal: Scientific Reports
doi: 10.1038/srep38174
Figure Legend Snippet: The bar graph represents mean values of the indicated miRNAs in plasma of DM1 patients compared to controls (CTR). Average values of cel-miR-39, miR106a and 17-5p were used for normalization (DM1 n = 103, CTR n = 111; ****p < 0.0001, *p < 0.05).
Techniques Used: Clinical Proteomics
Figure Legend Snippet: ( a ) Box plot of miR-133b levels in the plasma of DM1 and controls (CTR; ****p < 0.0001). ( b ) ROC curve illustrating sensitivity and specificity of plasma miR-133b in discriminating healthy from diseased patients. ( c ) Spearman’s inverse correlation between miRNA-133b fold change compared to CTR and muscle strength measured by MRC megascore. ( d ) Spearman’s direct correlation between miRNA-133b fold change compared to CTR and CK plasma levels. For all panels, DM1 n = 103, CTR n = 111.
Techniques Used: Clinical Proteomics
Figure Legend Snippet: The DM1-miRNA score was calculated averaging the fold changes of miR-1, -133a, -133b, -140-3p, -206, -27b, -454 and -574 in the plasma of DM1 and controls (DM1 n = 103, CTR n = 111). ( a ) Box plot of DM1-miRNA score levels in the plasma of DM1 and controls (CTR; ****p < 0.0001). ( b ) ROC curve illustrating sensitivity and specificity of the DM1-miRNA score in discriminating healthy from diseased patients. ( c ) Spearman’s inverse correlation between the DM1-miRNA score and muscle strength measured by MRC megascore. ( d ) Spearman’s direct correlation between the DM1-miRNA score and CK plasma levels.
Techniques Used: Clinical Proteomics
Figure Legend Snippet: The miR-133a/b score was calculated averaging the fold changes of miRNA-133a and -133b in the plasma of DM1 and controls (DM1 n = 103, CTR n = 111). ( a ) Box plot of miR-133a/b score levels in the plasma of DM1 and controls (CTR; ****p < 0.0001). ( b ) ROC curve illustrating sensitivity and specificity of the miR-133a/b score in discriminating healthy from diseased patients. ( c ) Spearman’s inverse correlation between the miR-133a/b score and muscle strength measured by MRC megascore. ( d ) Spearman’s direct correlation between the miR-133a/b score and CK plasma levels.
Techniques Used: Clinical Proteomics
Figure Legend Snippet: Multiple regression analysis, DM1 patients with stage of disease higher than 2.
Techniques Used:
Figure Legend Snippet: ( a ) The bar graph represents mean values of the indicated miRNAs in plasma of DM2 patients compared to controls (CTR). Average values of cel-miR-39, miR106a and 17-5p were used for normalization (****p < 0.0001, ***p < 0.001, **p < 0.01,*p < 0.05). ROC curves illustrating sensitivity and specificity of DM2-miRNA score ( b ), myomiR ( c ) and miR-133a/b score ( d ) in discriminating healthy from disease patients. (DM2 n = 30, CTR n = 30).
Techniques Used: Clinical Proteomics